Simultaneous Heart and Kidney Transplantation for Combined Cardiac and Renal Failure

• Published in: Transplantation proceedings 2006-09, Vol.38 (7), p.2135-2137
• Main Authors: Wang, S.S., Chou, N.K., Chi, N.H., Hsu, R.B., Huang, S.C., Chen, Y.S., Yu, H.Y., Ko, W.J., Chu, S.H., Tsai, M.K., Lee, P.H.
• Format: Article
• Language: English
• Subjects: Adult; Biological and medical sciences; Cardiology. Vascular system; Female; Fundamental and applied biological sciences. Psychology; Fundamental immunology; Heart; Heart Failure - complications; Heart Failure - surgery; Heart failure, cardiogenic pulmonary edema, cardiac enlargement; Heart Transplantation; Humans; Kidney Failure, Chronic - complications; Kidney Failure, Chronic - surgery; Kidney Transplantation; Male; Medical sciences; Renal Dialysis; Retrospective Studies; Surgery (general aspects). Transplantations, organ and tissue grafts. Graft diseases; Surgery of the urinary system; Tissue, organ and graft immunology; Transplantation, Homologous - pathology; Treatment Outcome
• ISSN: 0041-1345; 1873-2623
• DOI: 10.1016/j.transproceed.2006.06.002

Simultaneous heart and kidney transplantation (SHKT) is feasible for combined cardiac and renal failure. Herein we reviewed our 10-year experience in SHKT. Six patients underwent SHKT from June 1995 to December 2004. Their ages ranged from 13 to 63 years old with a mean of 45.5 ± 15.8 years. They were all men except one girl, who was the youngest (aged 13) who suffered from dilated cardiomyopathy with congestive heart failure and chronic renal failure due to systemic lupus erythromatosus. Because of aggravating heart failure, she changed from hemodialysis to peritoneal dialysis. Because of intractable heart failure, she underwent SHKT from a 24-year-old female donor. All received hemodialysis before SHKT. The indications for heart transplantation included dilated cardiomyopathy ( n = 3), ischemic cardiomyopathy ( n = 1), cardiac allograft vasculopathy ( n = 1), and cardiac allograft failure ( n = 1). The immunosuppressive protocol and rejection surveillance were these employed for heart transplantation. No operative mortality was noted in this study. The 1-year and 5-year survival rates were the same, 83%. The 10-year survival rate was 55%. No cardiac or renal allograft rejection was noted. No renal allograft loss was noted. There were two late mortalities: the one, who underwent redo heart transplantation for coronary artery vasculopathy died of cardiac allograft failure 1 year after SHKT. The other patient died of massive ischemic necrosis of the intestine at 6 years after SHKT. Our experience showed that SHKT had good short- and long-term results without increasing immunosuppressive doses. End-stage failure of either the heart or the kidney did not preclude heart plus kidney transplantation.